News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
550,963 Results
Type
Article (44744)
Company Profile (127)
Press Release (506092)
Section
Business (154985)
Career Advice (2385)
Deals (28960)
Drug Delivery (104)
Drug Development (70945)
Employer Resources (148)
FDA (15713)
Job Trends (12416)
News (278035)
Policy (30419)
Tag
Academia (2348)
Alliances (36658)
Alzheimer's disease (1280)
Approvals (15605)
Artificial intelligence (106)
Bankruptcy (307)
Best Places to Work (9492)
Biosimilars (78)
Biotechnology (78)
Breast cancer (97)
Cancer (863)
Career advice (1991)
Cell therapy (197)
Clinical research (55911)
Collaboration (274)
Compensation (157)
COVID-19 (2573)
Data (793)
Diabetes (131)
Diagnostics (5268)
Drug pricing (95)
Earnings (63908)
Employer resources (136)
Events (88257)
Executive appointments (209)
FDA (16130)
Funding (238)
Gene therapy (156)
GLP-1 (630)
Government (4026)
Healthcare (15442)
Infectious disease (2648)
Inflammatory bowel disease (97)
Interviews (445)
IPO (14326)
Job creations (3192)
Job search strategy (1665)
Layoffs (444)
Legal (7110)
Lung cancer (155)
Manufacturing (145)
Medical device (11399)
Medtech (11402)
Mergers & acquisitions (14641)
Metabolic disorders (386)
Neuroscience (1518)
NextGen Class of 2024 (5181)
Non-profit (3362)
Northern California (1088)
Obesity (235)
Opinion (189)
Patents (92)
People (43147)
Phase I (16505)
Phase II (24289)
Phase III (19852)
Pipeline (199)
Policy (77)
Postmarket research (2364)
Preclinical (6831)
Radiopharmaceuticals (210)
Rare diseases (184)
Real estate (4393)
Regulatory (20528)
Research institute (2089)
Resumes & cover letters (401)
Southern California (959)
Startups (2809)
United States (10150)
Vaccines (603)
Weight loss (202)
Date
Last 7 days (718)
Last 30 days (2492)
Last 365 days (32512)
2024 (27498)
2023 (36360)
2022 (46517)
2021 (50206)
2020 (47193)
2019 (38128)
2018 (28869)
2017 (28821)
2016 (27344)
2015 (30615)
2014 (24114)
2013 (19572)
2012 (21041)
2011 (21512)
2010 (19458)
Location
Africa (678)
Arizona (142)
Asia (31666)
Australia (5519)
California (2388)
Canada (919)
China (162)
Colorado (101)
Connecticut (114)
Europe (76544)
Florida (350)
Georgia (88)
Illinois (245)
Indiana (146)
Kansas (77)
Maryland (471)
Massachusetts (1961)
Michigan (115)
Minnesota (208)
New Jersey (730)
New York (739)
North Carolina (623)
Northern California (1088)
Ohio (99)
Pennsylvania (654)
South America (1043)
Southern California (959)
Texas (318)
Washington State (288)
550,963 Results for "recordati s p a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Recordati Announces Agreement to Acquire the Global Rights to Enjaymo®, Strengthening Its Rare Diseases Franchise
October 4, 2024
·
5 min read
Rare diseases
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights to a biologic for the treatment of cold agglutinin disease, with milestone payments of up to $250 million.
October 4, 2024
·
2 min read
·
Tristan Manalac
Deals
Donaldson Enters into Agreement to Acquire Minority Stake in Medica, S.p.A.
Donaldson Company, Inc., a leading worldwide provider of innovative filtration products and solutions, announced it has entered into a definitive agreement allowing the Company to purchase a 49% stake in Medica S.p.A.
April 29, 2024
·
5 min read
Essity included in S&P Global’s Sustainability Yearbook 2024
Hygiene and health company Essity has, for the third consecutive year, been included in S&P Global’s Sustainability Yearbook.
February 7, 2024
·
1 min read
Press Releases
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
October 29, 2024
·
2 min read
Deals
Biopharma Investment Activity Continued to Rise in Q2: J.P. Morgan
A report from J.P. Morgan shows an increase in biopharma activity so far this year and where some improvement can be made.
July 31, 2024
·
3 min read
·
Tyler Patchen
Drug Development
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
Elicio Therapeutics, Inc. announced new preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P.
June 27, 2024
·
6 min read
Deals
Enovis Completes Acquisition of LimaCorporate S.p.A
Enovis™ Corporation an innovation-driven, medical technology growth company, announced that it closed the acquisition of LimaCorporate S.p.A., a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions.
January 3, 2024
·
3 min read
FDA
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
Quanterix Corporation announced today that its Simoa ® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD).
March 4, 2024
·
4 min read
J.P. Morgan Raises Over $500M for First Biotech Venture Capital Fund
J.P. Morgan’s life sciences venture capital arm on Thursday announced it closed its first biotech fund, targeting companies in cardiometabolic disease, immunology, oncology and genetic medicine.
June 14, 2024
·
2 min read
·
Tyler Patchen
1 of 55,097
Next
